| Project/Area Number |
16K10134
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Kato Kenichi
Kawase Asami
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 薬疹 / 検査法 / 免疫学 / Stevens-Johnson症候群 / 中毒性表皮壊死症 / DLST / 薬剤性過敏症症候群 / ELISpot |
|---|
| Outline of Final Research Achievements |
The drug-induced lymphocyte stimulation test (DLST), also referred to as lymphocyte transformation test (LTT), is used to identify the culprit drug in cases of cutaneous adverse drug reactions (cADR). Although DLST is a widely used in vitro test, its sensitivity and specificity are unsatisfactory. Recent reports suggest that the detection of drug-induced interferon (IFN)-γ production using enzyme-linked immunoSpot (ELISpot) assay (conventional IFN-γ ELISpot) is useful for identifying culprit drugs in cADR cases. The modified IFN-γ ELISpot using activated PBMCs was more sensitive than the conventional IFN-γ ELISpot was for detecting drug-induced IFN-γ production, which could be a useful in vitro tool for identifying culprit drugs in cADR cases.
|
| Academic Significance and Societal Importance of the Research Achievements |
あらかじめ活性化・増殖した薬剤特異的Ｔ細胞によるIFN-γの産生や活性化を検出することで、より感度の高いin vitroの検査法が確立できたことにより、薬疹の原因薬剤特定の検査法としての臨床応用が期待できる。
|
